FDA Panel Will Weigh Mixed Efficacy Data For GSK’s Breo Ellipta In COPD

Agency says data supporting the relative contribution of the combination drug’s corticosteroid component, fluticasone, are “less robust” than data supporting the bronchodilatory effects of the long-acting beta-agonist component, vilanterol.